In this work, the discovery and description of PF‐07321332, a major bioavailable oral SARS‐
CoV‐2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent …

The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

Abstract Background Coronavirus disease 19 (COVID-19) is the disease caused by SARS-
CoV-2, a highly infectious member of the coronavirus family, which emerged in December …

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a new coronavirus in
the Coronaviridae family. The COVID-19 pandemic, caused by SARS-CoV-2, has …

To reduce the progression of the viral process in patients infected with COVID-19, new
treatments and drug active substances are needed. One of these drugs is Molnupiravir …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
worldwide pandemic since 2019, spreading rapidly and posing a significant threat to human …

Two potential genotoxic impurities were identified (PGTIs)-viz. 4-amino-1-((2R, 3R, 4S, 5R)-
3, 4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl) pyrimidin-2 (1H)-one (PGTI-1), and 1 …

Despite the approval of vaccines, monoclonal antibodies and restrictions during the
pandemic, the demand for new efficacious and safe antivirals is compelling to boost the …

Environmentally friendly and sustainable processes for the production of active
pharmaceutical ingredients (APIs) gain increasing attention. Biocatalytic synthesis routes …

Background COVID-19 is an illness caused by severe acute respiratory syndrome
coronavirus 2. Due to its rapid spread, in March 2020 the World Health Organization (WHO) …